Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus ACUVUE THERAVISION WITH KETOTIFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus ACUVUE THERAVISION WITH KETOTIFEN.
ACTIDIL vs ACUVUE THERAVISION WITH KETOTIFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer